[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Western University, Canada\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":650},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,45,75,107,136,159,184,208,236,260,287,309,330,349,376,400,432,454,478,504,529,552,583,605,623],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640591","post-osteoporotic-fracture-exercise-program-100640591",false,"NCT07595991","Post-osteoporotic Fracture Exercise Program","Community Osteoporosis Exercise Class for People Post Fracture","Inclusion Criteria:\n\n* Diagnosed with osteoporosis.\n* History of low trauma fracture within the past year\n* Cleared for physical activity using the get active questionnaire, 100 bpm resting heart rate or less, 160 mm Hg diastolic blood pressure or less\n* Able to understand and provide informed consent.\n* Residing within the study's geographic area (e.g., London, Ontario).\n\nExclusion Criteria:\n\n* Individuals who do not understand the English language\n* Medical conditions contraindicating participation in exercise (e.g., uncontrolled cardiovascular disease, severe respiratory illness).\n* Cognitive impairments that prevent informed consent or participation.\n* Recent major surgeries or medical events limiting physical activity.\n* Participation in conflicting clinical trials or rehabilitation programs.\n* Residents outside the designated study area.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Those with osteoporosis often have weaker bones and this leads to higher chances of fractures. Therefore, the investigators want to evaluate the feasibility and safety of group exercise classes specifically designed for individuals with osteoporosis who had an osteoporotic fracture. By focusing on this high-risk population, the investigators want to see whether such exercise interventions can be an option for improving bone health, reducing the risk of future fractures, and enhancing physical function without compromising safety.",[27,28],"Osteoporosis","Osteoporotic Fracture",[27,30,31],"Exercise Intervention","Osteoporotic fracture","NOT_YET_RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":21},"2026-09",{"date":40,"type":21},"2028-02",{"name":42,"class":43},"Western University, Canada","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100630237","phase-4-exercise-and-diabetes-interventions-to-improve-brain-health-in-older-adults-with-type-2-diabetes-100630237","NCT07485062","Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes","Metabolic Optimization and Training InterVentions for Aging and Type 2 Diabetes to Enhance Cognition: the MOTIVATE Study","MOTIVATE","Inclusion Criteria:\n\n1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.\n2. Community-dwelling\n3. Male or female\n4. Age ≥ 65 at the time of signing informed consent\n5. Glycated hemoglobin levels of ≥7% (i.e., A1c levels high enough to see intervention-related changes and increase eligibility for recruitment, but can exercise safely)\n6. Eligible for the Ontario Drug Benefit (inadequate glycemic control and on max tolerated dose of metformin or metformin contraindicated or inappropriate)\n7. Score \\>24\u002F30 on the Mini-Mental State Exam (MMSE)\n8. Score \\>6\u002F8 on the Lawton Instrumental Activities of Daily Living Scale (IADL)\n9. Have visual acuity of \\>20\u002F40 with or without corrective lenses\n10. Speak and understand English fluently\n11. Complete the Physical Activity Readiness Questionnaire (PAR-Q+) and obtain physician clearance to start a supervised exercise program\n12. Comfortable with a blood draw\n13. Not currently engaging in structured resistance exercise more than once per week\n\nExclusion Criteria:\n\n1. Have a medical condition for which semaglutide or exercise is contraindicated\n2. Use of a GLP-1 receptor agonist in the past 6 months (i.e., offers removal of Semaglutide from the system as it has a half-life of around 1 week; thus, 8-10 weeks are required for a washout.\n\n3\\) Have engaged regularly (\\>1\u002Fweek) in aerobic or RE within the past 6 months 4) Have a neurodegenerative disease (i.e., dementia) or psychiatric condition 5) Have had untreated depression in the past 6 months (6) Have experienced a recent vascular incident (i.e., stroke, myocardial infarction in the last 6 months.) (7) Have severe peripheral neuropathy, an active foot wound, or severe musculoskeletal\u002Fjoint disease (8) Active or untreated retinopathy (9) Taking psychotropic medications (excluding those for the treatment of depression)","65 Years",{"count":55,"type":21},164,[57],"PHASE4","Type 2 diabetes and low levels of physical activity are associated with an increased risk of cognitive decline in older adults. Improving blood sugar control and engaging in regular exercise may help support brain health and physical function in this population.\n\nThe MOTIVATE study is a randomized clinical trial designed to examine the effects of supervised exercise and diabetes treatment with semaglutide, alone or in combination, on cognitive function, physical health, and brain-related outcomes in older adults with Type 2 diabetes. Participants will be assigned to one of four study groups involving exercise training, control exercise, semaglutide treatment, or standard diabetes care.\n\nParticipants will complete supervised exercise sessions three times per week for 32 weeks, with some participants also receiving weekly semaglutide injections for 16 weeks. Assessments will include cognitive testing, physical and functional measures, blood-based metabolic markers, and brain imaging. This study aims to improve understanding of how exercise and diabetes treatments may support brain health in older adults with Type 2 diabetes.",[60,61],"Type 2 Diabetes","Cognitive Decline in Older Adults",[63,64,65,66,67,68,60],"Exercise Training","Semaglutide","Brain Health","Cognitive Function","Older Adults","Physical Activity",{"date":35,"type":36},{"date":71,"type":21},"2026-09-01",{"date":73,"type":21},"2029-05-01",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":44},"100588956","creatine-and-resistance-training-in-older-adults-with-mild-cognitive-impairment-100588956","NCT06948149","Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment","Examining the Effects of Creatine Supplementation and Resistance Training on Cognition and Brain Health in Older Adults With Mild Cognitive Impairment: a 26 Week Randomized Controlled Trial","We will include participants who: 1) are aged \\>60; 2) are living independently in the community; 3) have normal or corrected-to-normal vision and hearing; 4) read, write, and speak English fluently; 5) are right-handed (if participating in the MRI component); 6) have subjective feelings of memory decline in the past five years; 7) have telephone Montreal Cognitive Assessment (T-MoCA) scores \\\u003C19\u002F22; 8) have high independence, as indicated by Instrumental Activities of Daily Living (IADL) scale \\>6\u002F8; 9) have a Geriatric Depression Scale (GDS) score \\\u003C6\u002F15; 10) are able to exercise at a moderate pace using resistance training for 60 minutes 3x\u002Fweek; and 11) receive clearance from a physician to participate in an exercise program at baseline.\n\nWe will exclude participants who: 1) cannot partake or commit to exercise training 3x\u002Fweek for 26 weeks or have engaged in resistance training \\>1x\u002Fweek over the past three months; 2) cannot partake or commit to consuming a daily supplement for 26 weeks or have consumed nutritional supplements containing creatine monohydrate over the past three months; 3) have a known allergy to creatine monohydrate or dextrose; 4) have been diagnosed with a neurological disorder (e.g., Alzheimer's disease, Parkinson's disease); 5) have pre-existing kidney disease, heart disease, or liver abnormalities; 6) have one or more uncontrolled chronic or psychiatric conditions (e.g., hypertension, diabetes, depression, anxiety); 7) are taking medication that may impact kidney function (e.g., non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen); or 8) are ineligible or uncomfortable with blood sampling.","60 Years",{"count":84,"type":21},140,[24],"The goal of this 26-week trial is to learn if creatine supplementation and resistance training (i.e., weightlifting; exercise that increases muscle mass), alone and together, impact cognition, brain health, and physical function in older adults with mild cognitive impairment. Previous studies have shown that resistance training improves cognition and brain health in older adults. Creatine is naturally occurring in the human body and is known to decline with age. Studies have shown that creatine increases muscle mass and bone density in older adults when supplemented. Some research has suggested that creatine may also improve cognition and brain health. However, little is known about how creatine supplementation affects the aging brain and body alone and when combined with resistance training, especially in those with known cognitive impairment.\n\nIn this study, participants will be randomly assigned to one of four groups: 1) creatine and resistance training, 2) placebo and resistance training, 3) creatine and active control (balance and tone classes), or 4) placebo and active control. Participants in the creatine groups will take creatine every day during the study. Participants in the placebo groups will take a look-alike substance that contains no drug every day during the study. Participants in the resistance training groups will attend three 60-minute classes per week that target each major muscle group and will increase in difficulty during the study. Participants in the active control group will attend three 60-minute classes per week that will consist of balance, stretching, and range of motion exercises. This group accounts for variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.\n\nResearchers will collect information before and after the 26 weeks to see if creatine supplementation and\u002For resistance training have any effects on cognition, brain health, and\u002For physical function. The investigators suspect that both creatine supplementation and resistance training will improve cognition, brain health, and physical function alone. However, it is thought that the combination of creatine supplementation and resistance training will improve cognition, brain health, and physical function more.",[88,89,90],"Creatine","Exercise","Mild Cognitive Impairment (MCI)",[92,93,94,95,96,97,98,99],"older adults","physical activity","cognition","neuroimaging","mobility","mild cognitive impairment","creatine","dietary supplementation","RECRUITING",{"date":35,"type":36},{"date":103,"type":36},"2026-01-01",{"date":105,"type":21},"2027-12",{"name":42,"class":43},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100650569","phase-4-airway-dysfunction-occlusions-and-remodeling-copd-patients-and-mepolizumab-100650569","NCT07749001","Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab","Airway Dysfunction, Occlusions and RemodEling: COPD Patients and Mepolizumab (ADORE)","ADORE","Inclusion Criteria:\n\n* Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.\n* Provision of written, informed consent prior to any study specific procedures.\n* Males and females 55-85 years of age.\n* An eosinophilic phenotype with elevated BEC with a documented measurement of ≥ 300 cells\u002FµL at Baseline\u002Fscreening Visit 1.\n* CT mucus-count ≥ 3 on baseline\u002Fscreening CT OR on previous clinical CT acquired within last 12 weeks AND evaluable for mucus occlusions.\n* Moderate to severe COPD with frequent exacerbations, defined as:\n\n  * A clinically documented history of COPD as defined by the American Thoracic Society\u002FEuropean Respiratory Society for at least 1 year.\n  * A post-salbutamol FEV1\u002FFVC ratio of \\\u003C 0.70 and a post-salbutamol FEV1 ≥ 30% and \\\u003C 80% predicted at screening.\n  * A well-documented history (e.g., medical record verification) of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening:\n\n    1. At least one qualifying exacerbation must have occurred while participant is on ICS-LAMA-LABA.\n    2. Moderate exacerbations must have been treated with systemic corticosteroids.\n    3. Severe exacerbations are those requiring hospitalization (i.e., ≥ 24 hours)\n* Smoking status: Ex-cigarette smokers (quit ≥ 1 year) with a history of cigarette smoking of ≥ 10 pack-years at Baseline\u002Fscreening Visit 1.\n* Participants should be on maintenance inhaler therapy, defined as ICS+LAMA+LABA, either as multiple inhalers or a single combination inhaler for at least 3 months prior to Baseline Visit 1.\n* Participants on adjunctive COPD therapies such as roflumilast, chronic macrolide antibiotics may participate, provided they have been on these medications for at least 6 months, and on a stable dose for at least 3 months immediately prior to Baseline Visit 1. These participants should remain on these therapies for the duration of the study.\n* Women of non-childbearing potential will be included.\n\nSuch females will be:\n\nPermanently sterile due to one of the following procedures:\n\n1. Documented hysterectomy.\n2. Documented bilateral salpingectomy.\n3. Documented bilateral oophorectomy. For permanently sterile individuals due to an alternate medical cause other than the above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator discretion should be applied to determining study entry. If reproductive status is questionable, additional evaluation should be considered.\n\nNote: Documentation will stem from review of participant's medical records, medical examination, or medical history interview.\n\nPostmenopausal female. Females who are confirmed post-menopausal for ≥ 1year. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.\n\nA high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in participants not using hormonal contraception or HRT. In the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required.\n\nFemales on HRT and whose menopausal status is in doubt must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.\n\nExclusion Criteria:\n\n* Patient has an implanted mechanically, electrically, or magnetically-activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist).\n* In the Investigator's opinion, participant suffers from any physical, psychological, or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.\n* Participant is unable to perform spirometry or plethysmography maneuvers.\n* Participant is unable to perform MRI and CT breath-hold maneuvers.\n* Participants with any diagnosis of asthma at any time are excluded. A diagnosis of asthma should be based on both a history of typical respiratory symptoms combined with evidence of variable expiratory airflow limitation at the time of diagnosis consistent with GINA 2023 or other accepted guidelines.\n* Participants with α1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.\n* Participants with pneumonia, active COPD exacerbation at screening\u002Fbaseline visit, or lower respiratory tract infection within the 4 weeks prior to Baseline Visit 1.\n* Participants with a history of, or plan for lung volume reduction surgery\u002Fendobronchial valve procedure.\n* Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Baseline Visit 1 are excluded. Participants who are in the maintenance phase of a pulmonary rehabilitation program may participate.\n* Patients requiring oxygen supplementation for more than 12 hours per day are excluded. Non-continuous (i.e., 12 hours or less per day) oxygen is permitted up to 2 L\u002Fmin at screening.\n* Participants with Cor-pulmonale resulting in right heart failure, severe pulmonary hypertension.\n* Participants with chronic hypercapnia requiring BiPAP.\n* Participants with unstable cardiovascular disease.\n* Participants with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA, also known as Churg-Strauss Syndrome), or Eosinophilic Esophagitis.\n* Participants with a known, pre-existing parasitic infection within 6 months of Baseline Visit 1.\n* Participants with a current malignancy or previous history of cancer in remission for less than 12 months prior to Baseline Visit 1 (localized carcinoma of the skin or cervix resected for cure not excluded).\n* Participants with a known immunodeficiency (e.g., human immunodeficiency virus-HIV).\n* Participants with cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. NOTE: stable non-cirrhotic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B (in whom Hepatitis D (HDV) has been excluded)) or C are acceptable if participant otherwise meets entry criteria.\n* Participants with (historical or) current evidence of clinically significant, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which could affect the efficacy or safety analysis if the disease\u002Fcondition exacerbated during the study.\n* Previous exposure to monoclonal antibodies targeting IL-5\u002F5R, IL-4R\u002FIL-13, IL-33, or TSLP within 6 months or 5 half-lives, prior to Baseline Visit 1.\n* Previous documented failure with anti-IL-5\u002F5R or anti-IL-4R\u002FIL-13 therapy.\n* Other monoclonal antibodies: participants who have received any monoclonal antibody within 5 half-lives of Screening Visit 1.\n* Participants who have received short term use of oral corticosteroids within 4 weeks of Visit 1.\n* Previous randomization in the present study.\n* Concurrent enrolment in another clinical trial.\n* 12-lead ECG at Baseline Visit 1: participants with QT interval corrected with Fridericia's formula (QTcF) \\> 450 ms (or QTcF \\> 480 ms in participants with bundle branch block).\n\n  * QTcF is the QT interval corrected for heart rate according to Fridericia's formula that is selected for this study. It is either machine-read or manually over-read when not automatically machine read. This specific formula must be used to determine eligibility for an individual participant.\n  * Participants are excluded if an abnormal ECG finding from the 12-lead ECG conducted at Baseline Visit 1 is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the Investigator.\n  * Where a single ECG demonstrates a prolonged QTcF interval, obtain two more ECGs readings at a minimum of 2 minutes apart over a brief recording period (e.g., 5-10 minutes), The average of the triplicate QTcF measurements should be used to determine eligibility.\n* Participants with a known allergy or sensitivity to any of the study interventions or study treatment, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study or intolerance to another monoclonal antibody or biologic including history of anaphylaxis to another biologic.\n* Participants at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.\n* Participants with conditions that will limit the validity of informed consent to participate in the study, e.g., uncontrolled psychiatric disease or intellectual deficiency.\n* A known or suspected history of alcohol or drug abuse within 2 years prior to Baseline Visit 1.\n* For sputum induction, participants who have had previous bronchospasm or prior intolerance to a hypertonic saline solution, poorly controlled COPD on the day of sample collection, or oxygen saturation of less than 88% on room air will not take part in the induced sputum collection.\n* Female participants: Women of childbearing potential (after menarche) will NOT be enrolled.","55 Years","85 Years",{"count":118,"type":21},36,[57],"The goal of this study is to evaluate the effect of mepolizumab on patients with COPD using MRI and CT imaging as well as breathing tests. The study will evaluate the response to this medication after 24 and 48 weeks of treatment. The main questions it aims to answer are:\n\n1. Does mepolizumab improve ventilation defect percent as measured on 129-Xenon MRI in adults with COPD.\n2. Does mepolizumab improve the amount of mucus plugs in the lungs as measured by lung CT in adults with COPD.\n\nParticipants will:\n\n1. Take mepolizumab by subcutaneous injection every 4 weeks for the duration of the study.\n2. Visit Robarts 4 times over 48 weeks for tests and imaging.",[122],"COPD (Chronic Obstructive Pulmonary Disease)",[124,125,126,127],"129-Xenon","Pulmonary Function","Magnetic Resonance Imaging","COPD","2026-07-31",{"date":130,"type":36},"2026-08-06",{"date":132,"type":21},"2026-10-01",{"date":134,"type":21},"2028-04-01",{"name":42,"class":43},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":116,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":44},"100607704","phase-4-129-xe-mri-study-of-single-triple-therapy-inhaler-effects-in-copd-patients-with-moderate-severe-dyspnea-andor-poor-health-status-with-high-or-low-risk-of-exacerbation-100607704","NCT07192016","129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and\u002For Poor Health Status With High or Low Risk of Exacerbation","Mechanistic 129-Xe MRI Study of Single Inhaler FF\u002FUMEC\u002FVI Effects in COPD Patients With Persistent, Moderate-severe Dyspnea and\u002For Poor Health Status With High or Low Risk of Exacerbation","MUST","Inclusion Criteria:\n\n* patient understands study procedures and is willing to participate in the study as indicated by the patient's signature\n* provision of written, informed consent prior to any study specific procedures\n* males and females 50-85 years of age\n* stable COPD, currently on dual therapy LAMA\u002FLABA or ICS\u002FLABA or initial maintenance therapy for at least 3 months\n* mMRC score ≥2 and\u002For CAT score ≥10\n* Low risk subgroup: participant has experienced ≤1 exacerbation in the past year and no hospitalizations for COPD High risk subgroup: participant has experienced ≥2 exacerbations in the past year\n* Female of childbearing potential (after menarche) must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. Examples of effective birth control include:\n\n  1. True sexual abstinence\n  2. A vasectomized sexual partner\n  3. Implanon®\n  4. Female sterilization by tubal occlusion\n  5. Effective intrauterine device (IUD)\u002Flevonogestrel intrauterine system (IUS)\n  6. Depo-Provera™ injections\n  7. Oral contraceptive\n  8. Evra Patch™\n  9. Nuvaring™\n* Female permanently sterile due to: 1) documented hysterectomy, 2) documented bilateral salpingectomy, and 3) documented bilateral oophorectomy\n* Postmenopausal female: defined as female with no menses for 12 months without an alternative medical cause\n* Females of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from enrollment, throughout the study duration, and 8 weeks after last dose of study drug, with negative urine pregnancy test taken within 24 hr of any planned CT examination at Visit-1 through Visit 3\n* Male participants who are sexually active with a woman who can still have children, must agree to use a double barrier method of contraception (male condom with diaphragm or male condom with cervical cap) from the first dose of the study drug until 8 weeks after last dose\n\nExclusion Criteria:\n\n* Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist)\n* In the investigator's opinion, participant suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia\n* Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit\n* Participant is unable to perform spirometry or plethysmography maneuvers\n* Participant is unable to perform MRI and CT breath-hold maneuvers\n* Participant has an unstable cardiovascular, gastro-intestinal, hepatic, renal, neurologic, metabolic or psychiatric disease\n* Participation in any clinical trial of an investigational agent or procedure within three months prior to screening or during the study\n* Known history of allergy or reaction to the study drug formulation\n* Participant has a blood pressure of \\>150 mmHg systolic or \\>95 mmHg diastolic on more than 2 measurements done \\>5 minutes apart at Visit-1\n* Participants with a recently (\\\u003C2 months) documented diagnosis of asthma","50 Years",{"count":146,"type":21},60,[57],"The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting β2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are:\n\n* Does FF\u002FUMEC\u002FVI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD\n* Evaluate the relationships between the ventilation defect percent and lung function test results\n\nParticipants will:\n\n* Take the inhaler FF\u002FUMEC\u002FVI once daily for 12-weeks (optional 48-weeks)\n* visit Robarts 2 times (with optional 3rd visit) for tests and imaging",[150],"Chronic Obstructive Pulmonary Disease (COPD)",[125,127,124,126],"2026-07-29",{"date":128,"type":36},{"date":155,"type":36},"2026-04-24",{"date":157,"type":21},"2027-10",{"name":42,"class":43},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":166,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":44},"100606373","reverse-lung-airway-and-vascular-remodeling-in-asthma-remission-renorm-100606373","NCT07174713","REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)","ReNORM","Inclusion Criteria:\n\nParticipants eligible for inclusion in this study must meet all the following criteria:\n\n1. Participant understands study procedures and is willing to participate in the study as indicated by the patient's signature.\n2. Provision of written, informed consent prior to any study specific procedures.\n3. Males and females aged 18 to 80 years.\n4. Either diagnosed with severe asthma (GINA Step 5) and newly eligible for biologic therapy (based on ACQ-5, current treatment, exacerbation history, and blood eosinophils in accordance with approved criteria for omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab), or a healthy volunteer with no history of chronic lung disease, matched by age and sex. Healthy participants must have a lifetime combustible tobacco and\u002For cannabis (including vaping) consumption of ≤5 pack-years.\n5. Women of childbearing potential (after menarche) must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. Examples of effective birth control include:\n\n   1. True sexual abstinence\n   2. A vasectomized sexual partner\n   3. Implanon®\n   4. Female sterilization by tubal occlusion\n   5. Effective intrauterine device (IUD)\u002Flevonogestrel intrauterine system (IUS)\n   6. Depo-Provera™ injections\n   7. Oral contraceptive\n   8. Evra Patch™\n   9. Nuvaring™\n6. Women of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from enrollment, throughout the study duration, and 8 weeks after last dose of study drug, with negative urine pregnancy test result at Visit 1-5.\n7. Male participants who are sexually active must agree to use a double barrier method of contraception (male condom with diaphragm or male condom with cervical cap) from the first dose of the study drug until 8 weeks after last dose\n\nExclusion Criteria:\n\nParticipants fulfilling any of the following criteria are not eligible for inclusion in this study:\n\n1. Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist).\n2. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.\n3. Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.\n4. Participant is unable to perform spirometry or plethysmography maneuvers.\n5. Participant is unable to perform MRI and CT breath-hold maneuvers.",true,"80 Years",{"count":169,"type":21},200,[24],"In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in this response? While about 4.6 million Canadians live with asthma, \\~5-10% of patients have severe asthma meaning that multiple inhaled and systemic oral corticosteroid treatments have failed to improve symptoms and exacerbations, leading to lost work and school days and substantially diminished ability to participate in normal life. For such people, the vast majority of whom are middle aged and remember asthma as part of their entire lifespan, biologic immunomodulator therapies, which block the function of asthma inflammatory pathways, provide a final step-up therapy option. There is emerging evidence that prescribed in the right patient at the right time, the right biologic can result in clinical remission of asthma. While spontaneous clinical remission of asthma is rare, it has been documented in children in whom lung growth and remodeling is still possible. It remains unknown whether clinical remission in adults is accompanied by the reversal of pathologic remodeling, at the level of the airways and pulmonary vessels. This is critical to elucidate as investigators and physicians move forward with currently proposed criteria for \"complete asthma remission\". The inconvenient truth about asthma and age is that in older adult lungs, exposed to years of infection, exacerbations, smooth muscle remodeling and pulmonary vascular shunt, the mechanisms by which complete pathologic remission may be achieved are complex and poorly understood.\n\nTo address this knowledge gap, the investigators will evaluate 150 patients (Vancouver, Ottawa, Hamilton, London) (in three age tertiles 18-29; 30-59; 60-80) with severe asthma and 50 age- and sex matched healthy volunteers over 2-years using chest CT, MRI and pulmonary function tests. The investigators will use the pulmonary imaging measurements to generate an imaging-index of normal airway structure and function which will be compared with and significantly correlate with MR-guided bronchoscopic sample measurements made before and after 1-\u002F2-years of treatment. The investigators will reveal the pathobiologic relationship between age, asthma duration, clinical remission and imaging normalization with direct comparison to histology-based airway measurements.",[173],"Asthma; Eosinophilic",[175,176,177,178],"Hyperpolarized Xenon MRI","Clinical Remission","Biologic Therapy","Airway Remodeling",{"date":128,"type":36},{"date":132,"type":21},{"date":182,"type":21},"2030-10",{"name":42,"class":43},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100646890","phase-1-oral-and-sublingual-ketamine-100646890","NCT07683988","Oral and Sublingual Ketamine","A Comparative Analysis of the Pharmacokinetics of Oral and Sublingual Ketamine as Adjunctive Therapies in Major Depressive Disorder","Inclusion Criteria:\n\n* Participants must meet all the following criteria to be eligible for the study. Appendix B is a checklist that will be used by Dr. Hammound for screening, based on the following inclusion and exclusion criteria.\n\n  1. Age: Between 18 and 65 years (inclusive) at the time of screening.\n  2. Weight: Equal to or greater than 50 kg (110 lbs).\n  3. Diagnosis: A current diagnosis of Major Depressive Disorder (MDD), moderate to severe in intensity, as defined by the DSM-5 criteria.\n  4. Current Episode: Experiencing a moderate to severe Major Depressive Episode (MDE) at screening.\n  5. Ongoing Treatment: Actively receiving pharmacological treatment for MDD at the time of enrollment.\n  6. Treatment Resistance: Documented history of inadequate response to at least two antidepressant medications, each from a different pharmacological class, administered at an adequate dose and duration.\n  7. Capacity and Consent: Able and willing to provide written informed consent after understanding the nature, risks, and potential benefits of the study.\n  8. Clinical Oversight: Currently under the regular care of a psychiatrist or general practitioner (GP).\n  9. Support System: Has a responsible adult (e.g., family member or caregiver) who can accompany them from study visits or ensure safe transportation after ketamine has been used.\n  10. Able to speak, read and understand English\n\nExclusion Criteria:\n\n* Participants will be excluded if any of the following criteria apply:\n\n  1. Suicidality: Active suicidal ideation with plan or intent, or suicidal behavior, within the past 3 months.\n  2. Concomitant Medications: Use of medications that may pose a risk of respiratory depression or serious adverse events when combined with ketamine (e.g., benzodiazepines, opioids, barbiturates).\n  3. Medical Comorbidities: Presence or history of significant or unstable medical conditions that could interfere with study participation or pose a safety risk, including but not limited to cerebrovascular accident, cardiac decompensation, large vessel aneurysms, glaucoma etc.. Participants with clinically significant laboratory abnormalities, as determined by the investigator, will also be excluded.\n  4. Hypersensitvity to ketamine\n  5. Uncontrolled hypertension (blood pressure ≥140\u002F90 mmHg at screening, which may be repeated after 30 minutes rest)\n  6. Psychiatric Comorbidities: Diagnosis of bipolar disorder, psychotic disorders, or history of psychotic symptoms.\n  7. Substance Use: Clinically significant alcohol or substance use disorder within the last 6 months, as defined by DSM-5 criteria.\n  8. Cognitive Impairment: Any condition resulting in impaired capacity to understand or consent to participation or to comply with study procedures.\n  9. Pregnancy and Lactation: Pregnant or breastfeeding individuals.\n  10. Concurrent Research Participation: Participation in another interventional clinical trial or use of an investigational drug within the 30 days prior to screening.\n  11. Current or recent (within 90 days) treatment with ketamine (oral, IV or intranasal).\n  12. ECG demonstrates abnormalities like Qtc interval\\>470 ms or any arrhythmia reported as clinically significant or abnormal by the interpreting physician. Exclusionary findings would include uncontrolled atrial fibrillation, ventricular arrhythmias, heart block, or other abnormalities that could pose a safety risk with ketamine administration",{"count":192,"type":21},10,[194],"PHASE1","Major Depressive Disorder (MDD) is one of the most common and severe mental illnesses in the world. Ketamine treatment, especially intravenous ketamine (IVK) and intranasal esketamine (INE), is becoming more popular and is being used more. But these ways of administering aren't perfect. They mostly have problems with cost, accessibility, and the issues of administering. The oral and sublingual routes of ketamine are cheaper alternatives, but they haven't been looked into as much in the medical and academic circles. This is a small pilot feasibility study, involving ten patient participants who will be randomly assigned to take ketamine by oral and sublingual routes as part of a single-blind, crossover design. A local London pharmacy-Ultimate Care Compounding will provide the ketamine formulations.\n\nTen patients between 18 and 65 years old with Major Depressive Disorder will be recruited from the Mental Health Care Programs at LHSC, Victoria Hospital and SJHC, Parkwood Institute, (that has treatment resistant depression treatment focus). After a screening baseline visit, which will include clinical interviews with medication reconciliation, psychiatric evaluations, routine standard laboratory tests, and an electrocardiogram (ECG).\n\nDue to capacity limitations at the Centre for Clinical Investigation and Therapeutics (CCIT), a maximum of 5 participants will undergo pharmacokinetic sampling simultaneously, enrolment will proceed in two sequential groups with treatment order assigned by group. Group A (n=5): The first 5 eligible participants will receive oral ketamine in Treatment Period 1 and sublingual ketamine in Treatment Period 2. Group B (n=5): The next 5 eligible participants will receive sublingual ketamine in Treatment Period 1 and oral ketamine in Treatment Period 2. Recruitment for Group B will commence once Group A has completed the clinical intervention phase.\n\nDuring Monday and Thursday of each of Weeks 1 and 2, Group A will receive oral ketamine, while Group B will receive sublingual ketamine. Weeks 3 and 4 are a washout period. In Weeks 5 and 6, on Mondays and Thursdays, groups will switch to the other form of administration \\[See flowchart of study procedure\\]. Weeks 7 and 8 are washout periods to ensure consistency with the first half of the study and provide a similar framework for clinical assessments. Blood samples will be collected at 2 time points at the Center for Clinical Investigation and Therapeutics at University Hospital. The study goal is to help define safe and effective oral\u002FSL ketamine doses based on Pharmacokinetic profiles.",[197],"Major Depression Severe",[199,200],"ketamine","Depression","2026-06-28",{"date":203,"type":36},"2026-07-06",{"date":132,"type":21},{"date":206,"type":21},"2027-10-01",{"name":42,"class":43},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":44},"100546551","phase-4-obesity-management-for-kidney-transplantation-ok-transplant-2-100546551","NCT06396416","Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2","Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* BMI; 35 kg\u002Fm\\^2\n* 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis\n\nExclusion Criteria:\n\n* Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)\n* Type 1 diabetes\n* No access to semaglutide via drug coverage\n* Pregnant, breastfeeding or planning to become pregnant\n* Currently in a GLP-1RA or GLP-1RA\u002FGIP study or planning to be in one",{"count":146,"type":21},[57],"OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.\n\nWe will randomize participants with obesity, high-risk CKD\u002Fdialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.",[219,220],"Obesity","Chronic Kidney Disease",[222,223,224,225,226,227],"Weight Management","Transplant","GLP-1RA","Pilot Study","Registries","Pragmatic","2026-06-24",{"date":230,"type":36},"2026-06-29",{"date":232,"type":36},"2024-09-26",{"date":234,"type":21},"2026-12",{"name":42,"class":43},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":44},"100638507","the-purpose-of-this-pilot-study-is-to-determine-feasibility-of-a-randomized-controlled-trial-comparing-labral-repair-versus-reconstruction-in-patients-over-40-years-of-age-undergoing-hip-arthroscopy-for-fais-100638507","NCT07608237","The Purpose of This Pilot Study is to Determine Feasibility of a Randomized Controlled Trial Comparing Labral Repair Versus Reconstruction in Patients Over 40 Years of Age Undergoing Hip Arthroscopy for FAIS.","Labral Repair Versus Reconstruction in Symptomatic Femoroacetabular Impingement in Patients Over 40 Years of Age - A Randomized Controlled Trial","Inclusion:\n\n-Cam or pincer morphology who have failed a trial of conservative treatment\n\nExclusion:\n\n* Moderate concomitant OA (Tönnis 2+)\n* Have had previous hip surgery\n* Active joint or systemic infection\n* Significant muscle paralysis\n* Inflammatory arthropathies\n* Significant medical comorbidity that may alter effectiveness of surgical intervention\n* Active smoker\n* Major medical illness\n* Unable to speak and understand English\n* Psychiatric illness that precludes informed consent\n* Unwilling to be followed for 2 years","40 Years",{"count":245,"type":21},220,[24],"The purpose of this pilot study is to determine feasibility of a randomized controlled trial comparing labral repair versus reconstruction in patients over 40 years of age undergoing hip arthroscopy for FAIS. Specifically, we aim to: (1) estimate the proportion of eligible patients providing consent, (2) estimate the magnitude of the between-groups difference in the primary outcome (International Hip Outcome Tool \\[iHOT\\] - 33) to aid in sample size calculation for the full study, (3) estimate the compliance in completing the proposed outcome measures to determine the burden of questionnaire completion.",[249],"Femoral Acetabular Impingement",[251,252],"labral repair","labral reconstruction","2026-05-19",{"date":255,"type":36},"2026-05-27",{"date":71,"type":21},{"date":258,"type":21},"2028-12-31",{"name":42,"class":43},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":285,"locationsCount":286},"100507234","confirming-permanent-lack-of-blood-flow-to-the-brain-during-a-nrp-dcc-organ-transplant-100507234","NCT05884736","Confirming Permanent Lack of Blood Flow to the Brain During A-NRP DCC Organ Transplant","Confirming the Permanent Cessation of Intracranial Circulation During Abdominal Normothermic Regional Perfusion After the Determination of Death by Circulatory Criteria","CONCLUDE","Inclusion Criteria:\n\n* ≤ 18 years of age\n* Potential DCC donors whose families\u002Fsurrogate decision makers have consented to DCC organ donation according to current criteria of the participating transplant programs. These may include patients donating a liver, kidneys, pancreas, and\u002For lungs; please see Appendix A for organ specific donor inclusion criteria.\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age\n* DCC donors who proceed to donation following medical assistance in dying or those who are able to provide first-person consent at the time of donation\n* Injuries that anatomically preclude the use of neurological monitoring","75 Years",{"count":270,"type":21},30,"OBSERVATIONAL","This study aims to evaluate the surgical technique used in Abdominal Normothermic Regional Perfusion (A-NRP) in death determination by circulatory criteria (DCC) organ donors. The proposed study will demonstrate that there is no resumption of brain blood flow or activity during the A-NRP procedure. This will be assessed using multimodal neuromonitoring protocol that enables continuous focused monitoring of brain blood flow and activity during A-NRP. This will provide evidence that brain blood flow and activity does not resume during NRP and ensure donor safety in using this technique in standard of care practice.",[274],"Organ Transplant",[276,277,278,279],"A-NRP","neuromonitoring","brain activity","transplant","2026-05-15",{"date":253,"type":36},{"date":283,"type":36},"2024-04-02",{"date":105,"type":21},{"name":42,"class":43},2,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":294,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":44},"100504511","evaluation-of-the-transitional-and-lifelong-care-program-100504511","NCT05849285","Evaluation of the Transitional and Lifelong Care Program","Evaluating a Model of Transitional and Lifelong Care for Adults With Childhood-Onset Disabilities","Inclusion Criteria:\n\nEach participant dyad will consist of one person, of either sex and gender, who is over the age of 21 years with a childhood-onset disability, and the primary caregiver (based on contact hours) or support person, of either sex and gender, involved in their care. In cases where the patient participant is independent with care, a spouse or family member may still participate in the caregiver portion of the study.\n\n2\\. Patient participants will have continuously resided in Ontario during the years of 2015 to 2020 to facilitate full data retrieval from the administrative dataset.\n\n3\\. Healthcare providers, of any discipline, who provide care to adults with childhood-onset conditions in the TLC program.\n\nExclusion Criteria:\n\nPatient participants will be ineligible if they are in a phase of deterioration associated with a progressive health condition identified either personally or by the caregiver participant.","21 Years",{"count":296,"type":21},410,"The population cared for in the Transitional and Lifelong Care (TLC) clinic is youth and adults with childhood-onset disability, of which the large majority are adults with brain-based, neurodevelopmental conditions such as cerebral palsy, spina bifida and developmental disability. The TLC program was created to address the health inequities that have long existed for this population because of the gaps in care they experience once they transition from pediatric healthcare services to the adult healthcare sector. The TLC program offers coordinated and comprehensive management of co-occurring mental, social and physical health conditions for this group of adults with neurodiverse conditions. The proposed study will provide much needed evaluation of the TLC model as an intervention to provide transitional and lifelong care that reduces the barriers experienced because of the undefined clinic path - potentially more appropriately referred to as a \"cliff\" by a Freeman et al., (2015) - for these individuals. With appropriate evidence of effectiveness, scaling of the TLC program to other Ontario Health regions and more widely across Canada would improve access healthcare providers who are knowledgeable and competent in the management of physical and mental health conditions for adults with neurodiverse conditions as well as service integration and coordination between social and health sectors. The TLC clinic was co-designed with adults with neurodiverse conditions and health care providers in 2014 and represents a significant and sustainable change in the way healthcare has been delivered for this population in the Ontario Health West region over the last 7 years. More than 750 people have accessed coordinated and comprehensive care from Physiatrists, a Nurse Practitioner, Social Worker, Physiotherapist, Occupational Therapist, Speech Language Pathologist, Registered Dietitian and Rehabilitation Therapist in the TLC program since it began, documenting the effectiveness of this care has the power to re-shape care received for adults with neurodiverse conditions that onset in childhood in Canada.",[299,300,301],"Cerebral Palsy","Spina Bifida","Developmental Disability","2026-02-25",{"date":304,"type":36},"2026-02-27",{"date":306,"type":36},"2024-01-03",{"date":105,"type":21},{"name":42,"class":43},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":18,"enrollmentInfo":315,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":44},"100621602","feasibility-and-usability-of-a-mobile-app-for-monitoring-and-managing-functional-movement-disorders-100621602","NCT07372755","Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders","Inclusion Criteria:\n\n* Age ≥18\n* Diagnosed with a functional movement disorder\n* Own a smartphone\n* Ability to read and understand English\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Acute psychiatric crisis\n* Limitations that make it impossible to use a smartphone app",{"count":192,"type":21},"People with FMD may experience symptoms such as tremor, jerks, spasms, or difficulty walking. These symptoms are not caused by damage to the brain or nerves. Instead, they happen because the brain is not sending or processing signals in the usual way. Symptoms can change from day to day, and stress, emotions, or certain situations may make them better or worse.\n\nRight now, patients are often asked to remember how their symptoms have been since their last clinic visit or to write things down in a notebook. This can be hard to do and may not give an accurate picture of what is happening. Because of this, doctors and patients may miss important patterns or triggers, and it can be harder to know which coping strategies are helpful.\n\nTo improve this, our team has created a mobile app that allows people with FMD to easily record their symptoms, stress level, and mood, in real time. The app also includes simple self-help tools that may support symptom management. Before using this app more widely, we want to find out (1) whether patients can use it as intended and (2) whether they find it easy and helpful to use. This study will help us understand if the app is practical for use in an FMD clinic and how it could be improved.",[318],"Functional Movement Disorder",[320,321],"functional movement disorder","mobile app","2026-01-19",{"date":324,"type":36},"2026-01-28",{"date":326,"type":21},"2026-02-01",{"date":328,"type":21},"2028-06-01",{"name":42,"class":43},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":166,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":44},"100616184","action-outcome-latencies-as-a-measure-of-sense-of-agency-in-functional-movement-disorders-100616184","NCT07302308","Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.","Inclusion criteria for patients: Inclusion criteria for patients:\n\n1. Diagnosed with clinically definite functional movement disorder\n2. Age \\>18 years.\n3. Able to read and understand English.\n\nInclusion criteria for healthy subjects:\n\n1. Age \\>18 years.\n2. Able to read and understand English\n\nExclusion criteria for patients:\n\n1. Moderate to severe action tremor in the dominant hand limiting the ability to perform the task.\n2. Upper limb peripheral neuropathy.\n3. Unable to read and understand English.\n\nExclusion criteria for healthy subjects:\n\n1\\. Unable to read and understand English.",{"count":270,"type":21},"Functional movement disorders (FMD) are among the most common neurological conditions seen in clinical practice, yet they are poorly understood and often misdiagnosed. Impaired self-agency, the sense of controlling one's actions, is a key feature of FMD. Studies using functional MRI have shown reduced activation and connectivity in the right inferior parietal lobule, a region associated with agency.\n\nThe sense of agency consists of two components: the feeling of agency, which is an implicit, low-level sense of control over voluntary actions, and the judgment of agency, which is the conscious attribution of actions to oneself. While the feeling of agency is often measured using intentional binding tasks, judgment of agency is assessed using self-reported scales. While studies have explored intentional binding as a measure of implicit agency in FMD, few have systematically investigated judgment of agency. This study aims to fill this gap by introducing a novel approach that quantitatively evaluates judgment of agency in FMD patients using action-outcome latencies as an objective metric.",[318],[320,340,341],"sense of agency","judgment of agency",{"date":343,"type":36},"2026-01-21",{"date":345,"type":21},"2026-01-31",{"date":347,"type":21},"2028-01-31",{"name":42,"class":43},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":44},"100525903","survivorship-after-hnc-a-randomized-controlled-trial-evaluating-patient-care-and-adherence-to-follow-up-100525903","NCT06127784","Survivorship After HNC: A Randomized Controlled Trial Evaluating Patient Care and Adherence to Follow-up","Survivorship After Head and Neck Cancer: A Randomized Controlled Trial Evaluating Patient Care and Adherence to Follow-up","Patient Participants\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Willing to provide informed consent\n* Diagnosis of stage I-IVA head and neck mucosal cancer (larynx, hypopharynx, oral cavity, oropharynx, nasopharynx)\n* Last definitive treatment (surgery, chemotherapy, radiotherapy) between 3 and 6 months prior to enrollment\n* English speaking, reading and writing\n\nExclusion Criteria:\n\n* Second concurrent non-cutaneous malignancy\n* Metastatic disease\n* Clinically apparent cognitive impairment\n* Suspected residual disease after treatment completion",{"count":357,"type":21},176,[24],"Treatment summary and survivorship care plans (TSSPs) are poorly studied in Head and Neck Cancer (HNC) patients, and given the high frequency of unmet needs, this patient population has potentially the most to benefit from the implementation of TSSPs. A preliminary feasibility randomized control trial (RCT) at London Regional Cancer Program (LRCP) of 18 patients with HNC evaluating the implementation of TSSPs, found that patients assigned to the intervention group had a 15% higher rate of physician implementation of survivorship care needs compared to the usual care group (40% versus 25%, respectively). Results of the pilot study indicated that successful execution of TSSPs and counselling sessions for HNC patients is feasible. In follow up to the initial feasibility trial, the present investigation seeks to execute a large-scale randomized controlled trial. Three hundred and four patients who were treated at the London Regional Cancer Program (LRCP) for HNC will be randomly assigned to either usual care or a survivorship care plan (TSSP) intervention (90 patients in each arm). The intervention will consist of the delivery of a TSSP and a motivational interviewing counseling session with a clinical nurse specialist tailored to the needs of this vulnerable cancer population. The primary objective of the study is to evaluate the delivery of a TSSP during a one-on-one motivational interviewing counselling session with HNC survivors to determine whether the intervention results in improved implementation of recommendations for HNC survivors compared to usual care. Secondary study objectives will evaluate quality of life and satisfaction with care at 12 months post-intervention between the usual care and intervention group. Primary care providers of patients assigned to the intervention group will also be surveyed on the utility of the TSSP.",[361,362],"Head and Neck Cancer","Survivorship",[364,365,366,367],"Motivational Interviewing","Counselling","Survivorship Care Plan","Treatment Adherence","2025-11-14",{"date":370,"type":36},"2025-11-18",{"date":372,"type":36},"2025-05-01",{"date":374,"type":21},"2027-07-01",{"name":42,"class":43},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":386,"conditions":387,"keywords":390,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":397,"leadSponsor":399,"locationsCount":44},"100560597","comorbidity-management-in-rheumatic-disease-100560597","NCT06579222","Comorbidity Management in Rheumatic Disease.","Comorbidity Management in Rheumatic Disease: Assessing a Potential Care Gap in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Patients of the Waterloo Rheumatology Community Clinic\n* Aged 18 to 80 years of age\n* Diagnosis of rheumatoid arthritis\n* Minimum of limited working proficiency in English\n* No significant cognitive impairment that can inhibit their ability to engage in the study\n\nExclusion Criteria:\n\n* Age less than 18 years or greater than 80 years\n* Significant cognitive impairment that impedes ability to engage in the study\n* Unwilling to participate in the study\n* Patients currently pregnant will be excluded from the study",{"count":384,"type":21},199,[24],"Rheumatoid arthritis is a disease where the immune system attacks the body by mistake, causing inflammation of the joints and other body parts. People with rheumatoid arthritis are at higher risk of infections, heart problems, and bone issues compared to others. They regularly see rheumatologists, arthritis care physicians, to manage their disease. However, managing these other health problems alongside their main treatment is difficult for rheumatologists due to limited resources. This clinical study is being conducted to see if adding a family doctor to a team of rheumatologists can help. Rheumatologists will complete a case report form about the patient's health and send them to a special family physician clinic. This clinic will focus on improving vaccination against diseases, heart health, and bone strength. They will check if patients need special vaccines to protect them from infections. They will screen for heart disease using blood pressure measurements, and order blood work for high cholesterol and diabetes if needed. They will also review bone health and send people for tests to check their bone density if needed. A change in routines and medications may be recommended after their checkup. Rheumatologists will complete another case report about the patient's health 6 months after their family doctor appointment. The study will assess how these markers of health management improve after this family doctor joins the team. It hopes to prove that this new way of working in the community will give people with rheumatoid arthritis better protection against certain infections, heart problems and weak bones.",[388,389],"Rheumatoid Arthritis","Comorbidities and Coexisting Conditions",[391,392],"rheumatoid arthritis","comorbidities","2025-10-01",{"date":395,"type":36},"2025-10-07",{"date":372,"type":36},{"date":398,"type":21},"2026-12-19",{"name":42,"class":43},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":409,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":44},"100608649","enhancing-patient-comfort-and-reducing-anxiety-during-flexible-cystoscopy-and-bladder-instillation-in-bladder-cancer-patients-a-randomized-controlled-trial-and-observational-study-100608649","NCT07204301","Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study","Flexi-comfort","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of bladder cancer undergoing diagnostic\u002Fsurveillance flexible cystoscopy or intravesical bladder instillation in the outpatient urology clinic\n* Able to provide informed consent\n\nExclusion Criteria:\n\nIndividuals \\\u003C18 years of age.\n\n* Individuals unable to provide informed consent (e.g., diminished or fluctuating capacity).\n* Individuals unable to communicate verbally with study staff (e.g., severe speech\u002Fhearing impairment without assistive support available).\n* Individuals with severe cognitive impairment or acute distress at the time of approach that prevents informed consent.\n* Individuals with known hypersensitivity or allergy to lidocaine, topical anesthetic gel, or any components used in the procedure.\n* Individuals for whom, in the opinion of the treating urologist, participation would pose undue clinical risk or interfere with urgent clinical care.",{"count":408,"type":21},378,[24],"The goal of this clinical trial is to learn if certain comfort-enhancing interventions can reduce pain and anxiety during flexible cystoscopy and bladder instillation in patients with bladder cancer. The main questions it aims to answer are:\n\n* Do these interventions reduce patient-reported anxiety during the procedure?\n* Do these interventions reduce patient-reported pain or discomfort during the procedure?\n\nResearchers will compare patients receiving comfort interventions (such as timing of anesthetic gel, calming music, or visual distraction) to those receiving standard care to see if these changes improve patient experience.\n\nParticipants will:\n\n* Undergo a flexible cystoscopy or bladder instillation as part of their usual care\n* Be randomly assigned to receive one or more comfort interventions, or standard care\n* Complete short questionnaires about their pain, comfort, and anxiety",[412],"Bladder Cancer",[414,415,416,417,418,419,420,421,422,423],"flexible cystoscopy","bladder instillation","Patient comfort","Anxiety reduction","Pain management","Urologic oncology","Bladder cancer surveillance","Patient-reported outcomes","Procedural anxiety","Minimally invasive urology","2025-09-24",{"date":426,"type":36},"2025-10-02",{"date":428,"type":21},"2025-11-01",{"date":430,"type":21},"2026-07-01",{"name":42,"class":43},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":166,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":439,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":44},"100355555","longitudinal-study-of-xenon-129-mri-imaging-effects-of-cannabis-smoking-100355555","NCT03909477","Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking","Longitudinal Study of Xenon-129 MRI Imaging of Effects of Cannabis Smoking on Lung Structure and Function","Inclusion Criteria:\n\n* Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature\n* Provision of written, informed consent prior to any study specific procedures\n* Males and females aged 18-85\n* Current or former cannabis smoker (medicinal or recreational) with or without concurrent tobacco smoking history\n* Participant is able to perform reproducible pulmonary function testing (i.e. the 3 best acceptable spirograms have Forced Expiratory Volume in 1 second (FEV1) values that do not vary more than 150 millilitres)\n* Participant is able to perform a breathhold for 16s\n* FEV1 \\> 25% predicted\n* Forced Vital Capacity (FVC) \\> 25% predicted and \\>0.5 litres\n\nExclusion Criteria:\n\n* Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand written material\n* Participant is medically unstable in the opinion of the Principal Investigator\n* Participant has a daytime room air oxygen saturation \\\u003C90% while lying supine\n* Participant is unable to perform spirometry or plethysmography maneuvers\n* Patient is pregnant at time of enrolment\n* In the opinion of the investigator, patient suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia\n* Patient has implanted mechanically, electrically or magnetically activated device or any metal in their body, which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) - at the discretion of the MRI Technologist.",{"count":169,"type":21},"This is a longitudinal study of the long-term health impact of cannabis smoking on the lungs. Participants will be followed over a period of 3 years, and impacts of cannabis smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.",[442,443,444,445],"Cannabis Use","Cannabis Smoking","Marijuana Smoking","Marijuana Usage","2025-08-11",{"date":448,"type":36},"2025-08-15",{"date":450,"type":36},"2022-06-01",{"date":452,"type":21},"2030-12-01",{"name":42,"class":43},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":166,"sex":17,"minAge":461,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":44},"100409809","novel-pulmonary-imaging-of-lung-structure-and-function-in-e-cigarette-smokers-100409809","NCT04616313","Novel Pulmonary Imaging of Lung Structure and Function in E-cigarette Smokers","Novel Pulmonary Imaging of Lung Structure and Function in Symptomatic and Asymptomatic E-cigarette Smokers","Inclusion Criteria:\n\n* Written informed consent must be directly obtained from legally competent participants before any study-related assessment is performed.\n* Male and female participant age ≥16 years.\n* Participant has recently started vaping, \\>1 and \\\u003C5 years weekly use.\n* 70 participants will be c-cigarette never users.\n* 70 participants will be former or current c-cigarette users.\n* 10 asymptomatic age and sex-matched healthy people who have never used e- or c-cigarettes will be controls.\n\nExclusion Criteria:\n\n* Participants with contraindications for undergoing an MRI such as participants with MRI-sensitive implants, tattoos with MRI-sensitive dye and severe claustrophobia.\n* Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand written material.\n* Participant unable to perform spirometry or plethysmography maneuvers.","16 Years",{"count":463,"type":21},150,"This is a longitudinal study of the long-term health impact of e-cigarette smoking on the lungs. Participants will be followed over a period of 5 years, and impacts of e-cigarette smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.",[466],"E Cigarette Use",[468,469,470,126],"e-cigarette smoking","pulmonary function","Xenon-129","2025-08-08",{"date":473,"type":36},"2025-08-14",{"date":475,"type":36},"2023-01-17",{"date":105,"type":21},{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":486,"minAge":18,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":44},"100587751","phase-2-a-clinical-trial-of-primary-retroperitoneal-lymph-node-dissection-in-patients-with-testicular-seminoma-with-limited-retroperitoneal-metastases-100587751","NCT06932458","A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases","A Phase II Single-arm Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases","RPLND-Seminoma","Inclusion Criteria:\n\n1. Adult patients (\\>18 years) with pure seminoma on radical orchiectomy specimen.\n2. Initial CS I presentation with subsequent retroperitoneal relapse on surveillance, or de novo CS II at presentation.\n3. Axial imaging of lymphadenopathy within 8 weeks of the date of RPLND\n\n   1. No more than 2 enlarged retroperitoneal lymph nodes, each no more than 3cm in the primary landing zones.\n   2. Suitable for proposed bilateral RPLND template\n4. Serum tumour markers (alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH)) must all be within normal limits within 2 weeks of planned RPLND\n\nExclusion Criteria:\n\n1. Any condition deemed by the treating surgeon to pose an unacceptable risk for retroperitoneal lymph node dissection\n2. Any non-seminoma component on the orchiectomy specimen.\n3. AFP \\>20 at any time point, pre- or post-orchiectomy.","MALE",{"count":270,"type":21},[489],"PHASE2","Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%).\n\nFor many years, the management of patients with CS IIA\u002FB seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients",[492],"Testicular Cancer",[494,495],"Seminoma","Retroperitoneal lymph node dissection","2025-07-16",{"date":498,"type":36},"2025-07-20",{"date":500,"type":21},"2025-07-17",{"date":502,"type":21},"2030-06-01",{"name":42,"class":43},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":44},"100522864","changes-in-postural-stability-following-tha-for-oa-100522864","NCT06088160","Changes in Postural Stability Following THA for OA","Changes in Postural Stability and Balance Confidence in People After Elective Unilateral Total Hip Arthroplasty for Osteoarthritis: A Prospective Cohort Study","CPS","Inclusion Criteria:\n\n* ≥ 60 years of age, scheduled to receive an elective unilateral THA (DA or DL approach) for OA\n* Ambulatory for a minimum of 10 meters with or without a mobility aid but without the assistance of another person\n* Able to read, write and speak English\n* Able to provide consent\n\nExclusion Criteria:\n\n* Bilateral THA\n* Underwent THA surgery for a diagnosis other than OA\n* Any condition that will prevent participants from completing the study such as having a significant neurological, cardiovascular, musculoskeletal condition as denoted by their physician.",{"count":513,"type":21},80,"Total hip arthroplasty (THA) is a common surgery that eases pain, restores functional movement, and improves the overall quality of life in people with severe hip osteoarthritis (OA). Unfortunately, problems with postural stability, commonly known as balance, are still noticed in people even years after the surgery. These postural stability problems typically result in falls. The aim of the proposed study is to investigate how THA surgery affects a person's overall quality of life, both physically and psychologically, in terms of postural stability and balance confidence (self-efficacy) within the first three months after THA for osteoarthritis. This prospective cohort study will focus on people over 60 years old.",[516],"Osteoarthritis, Hip",[518,519,520,521,522],"Postural stability","Total hip arthroplasty","Balance confidence","Osteoarthritis","Fall",{"date":498,"type":36},{"date":525,"type":36},"2023-12-27",{"date":527,"type":21},"2025-11",{"name":42,"class":43},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":538,"conditions":539,"keywords":542,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":44},"100350560","3d-ultrasound-imaging-liver-and-kidney-100350560","NCT03844399","(3D) Ultrasound Imaging Liver and Kidney","Use of 3-Dimensional (3D) Ultrasound Imaging to Guide the Treatment of Abdominal Tumours Using Focal Ablation or Biopsies","Inclusion Criteria:\n\n* • Patients who are scheduled for standard care liver or kidney ablation or biopsy\n\nExclusion Criteria:\n\n* None",{"count":537,"type":21},40,"This study is to assess the addition of 3D ultrasound guidance during standard care ablation or biopsies of liver or kidney tumours. 3D ultrasound only differs from conventional 2D ultrasound in that the ultrasound transducer is mounted on a special assembly that moves the transducer in precise, stepped movements while a succession of 2D images are collected by the computer. Special software written specifically for 3D ultrasound precisely aligns these 2D images into a 3-demensional volume , allowing area in question to be viewed in many different planes. 3D ultrasound is a safe, fast, non-invasive imaging procedure. Ultrasound images will be checked against the pre- and post- procedure CT images to make sure the tumours were completely removed or properly targeted during biopsy.",[540,541],"Liver Cancer","Kidney Cancer",[543,544,545],"Diagnostic","Intervention","3D Ultrasound",{"date":498,"type":36},{"date":548,"type":36},"2020-10-03",{"date":550,"type":21},"2027-02",{"name":42,"class":43},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":559,"enrollmentInfo":560,"targetDuration":4,"studyType":22,"phases":562,"briefSummary":563,"conditions":564,"keywords":568,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":580,"leadSponsor":582,"locationsCount":44},"100585969","caregiver-training-to-support-children-with-social-communication-challenges-100585969","NCT06909279","Caregiver Training to Support Children With Social Communication Challenges","The More Than Words® Program for Parents of Young Children With Social Communication Challenges: A Pilot Pragmatic Randomized Waitlist-Control Trial","Inclusion criteria:\n\n1. The child is under 48 months of age at the time of study enrolment.\n2. The child has delays in social communication and play skills according to the clinical assessment of the child's community SLP.\n3. The parent (or other primary caregiver) has a smart phone, tablet, or computer with webcam and internet access to attend the virtual MTW sessions and complete study measures\n4. The parent is available to attend the 13-week virtual MTW program (which includes 9 online group sessions on Saturday mornings or Monday evenings).\n5. The parent is comfortable communicating and filling out forms in English.\n\nExclusion Criteria:\n\nFailure to meet the inclusion criteria outlined above.","47 Months",{"count":561,"type":21},72,[24],"\"More Than Words® - The Hanen Program® for Parents of Autistic Children or Children Who May Benefit from Social Communication Support\" is a family-focused intervention program delivered by a speech-language pathologist (SLP). The goal of More Than Words is to empower parents to be the main facilitator of their child's social communication development, which increases the child's opportunities to develop social communication skills in everyday situations. It is one of the programs offered to families who receive services from Ontario's Preschool Speech and Language program, although some regions are not able to offer it at all or are only able to offer a shortened version of the program. The Hanen Centre recently made updates to the More Than Words program to allow it to be delivered virtually (online) and to align with the latest evidence.\n\nPast research has found some evidence that the More Than Words program is effective, but knowledge is needed about the latest version of the program, including how effective it is when delivered online. It is important to understand who this program works best for and why. The purpose of the current study, called a pilot study, is to test a study plan that could be used in a future large study to answer these questions.\n\nIn this pilot study, the investigators will test procedures for comparing the outcomes of families who receive the More Than Words program to families who have not yet received it. Additionally, procedures for understanding varying responses to treatment will be tested. The study aims to determine whether the methods used for recruiting families, delivering the program, and monitoring progress are practical and function as expected in preparation for the future large-scale study.",[565,566,567],"Autism Spectrum Disorder","Suspected Autism","Social Communication Challenges",[569,570,571,572,573,574,575],"Autism","Parent mediated","Hanen More Than Words","Tele practice","Social communication challenges","pilot pragmatic RCT","virtual care","2025-05-06",{"date":578,"type":36},"2025-05-11",{"date":576,"type":36},{"date":581,"type":21},"2026-07",{"name":42,"class":43},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":44},"100560978","guided-icbt-for-adults-with-tinnitus-in-canada-a-randomized-controlled-trial-100560978","NCT06584175","Guided ICBT for Adults With Tinnitus in Canada: A Randomized Controlled Trial","Guided Internet-Delivered Cognitive Behavioural Therapy for Adults With Tinnitus in Canada: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. adults (18-79 years);\n2. diagnosed with tinnitus for more than 6 months;\n3. ability to read and write in English;\n4. cognitive capacity to consent and participate in the therapeutic process;\n5. able to access the technology required for the program (telephone, computer, internet);\n6. Canadian residents;\n7. A score of 25 or above on the Tinnitus Functional Index (TFI) suggesting the need for tinnitus care.\n\nExclusion Criteria:\n\n1. have significant cognitive impairments that impact their ability to participate in the therapy;\n2. are currently involved in another psychotherapeutic intervention on a regular basis;\n3. present with severe mental health disorder that would be better treated in person (e.g., severe suicide ideation, severe substance abuse, recent history of psychosis, mania);\n4. have tinnitus as a consequence of a medical disorder, still under investigation;\n5. are reporting objective, pulsatile, or unilateral tinnitus, which have not been investigated medically;\n6. are undergoing any tinnitus therapy concurrently with partaking in this study.","79 Years",{"count":592,"type":21},82,[24],"The goal of this randomized controlled trial is to learn if guided Internet-delivered Cognitive Behavioural Therapy can treat tinnitus-related distress and its associated comorbidities such as anxiety, depression, insomnia, and quality of life among adult tinnitus patients in Canada. The main questions it aims to answer are:\n\n* Does guided internet-delivered cognitive behavioural therapy for the treatment of tinnitus reduce tinnitus-related distress and tinnitus-associated comorbidities (depression, anxiety, insomnia, quality of life) among adult tinnitus patients aged 18-79 years in Canada from pre-treatment to post-treatment and 3-month follow-up?\n* Do participants in the personalized ICBT treatment group show worse improvements in patient-reported outcomes from pre-treatment to post-treatment and 3-month follow-up than the standard ICBT control group?\n\nThe researchers will compare a personalized ICBT program to a standard ICBT program to investigate if participants in the personalized ICBT program will show no worse improvements in patient-reported outcomes from pre-treatment to post-treatment and 3-month follow-up than the active comparator, the standard ICBT program.\n\nParticipants will:\n\n* Receive either a personalized ICBT program or a standard ICBT program delivered over 8 weeks consisting of 21 modules.\n* Receive guided support of approximately 10-15 minutes per week by video chat or phone from a trained Guide over the 8-week duration of the program.\n* Complete assessments at baseline, post-intervention, and 3-month follow-up through online REDCap surveys with automatic emails and telephone reminders.",[596],"Tinnitus","2025-04-09",{"date":599,"type":36},"2025-04-13",{"date":601,"type":21},"2025-09-15",{"date":603,"type":21},"2026-08-31",{"name":42,"class":43},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":622,"locationsCount":44},"100525227","breast-3dus-abus-system-comparison-100525227","NCT06118996","Breast 3DUS ABUS System Comparison","Comparing the Efficacy of 3D Ultrasound Imaging of Breast Pathology Between a Custom ITA Device and Invenia™ ABUS System by GE Medical","Inclusion Criteria:\n\n* Adult Patients who are scheduled for screening ABUS\n* Adults Patients who are scheduled for short term follow-up with ABUS.\n* Must be at least 18 years of age or older.\n* Must be proficient in English (reading\u002Fwriting).\n\nExclusion Criteria:\n\n* Patients with breast implants.\n* Patients with contraindication for ABUS.\n* Patients who cannot tolerate ABUS.",{"count":270,"type":21},[24],"This comparative study will recruit 30 females who are scheduled for mammography and ultrasound assessment. The clinical 2D ultrasound is performed routinely, and the research portion of this study will add a few extra 3-D ultrasound images during the procedure. The ultrasound imaging laboratory under the direction of Dr. Aaron Fenster has developed a customized device designed to acquire 3D ultrasound of the breast using a commercial ultrasound machine. The purpose is to see how well 3-dimensional ultrasound acquire from that device is able to visualize tumours and other key features in comparison to the clinical system InveniaTM developed by GE Medical.",[616],"Breast Diseases",[545,544],{"date":599,"type":36},{"date":620,"type":36},"2024-08-18",{"date":234,"type":21},{"name":42,"class":43},{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":44},"100514216","non-invasive-brain-stimulation-paired-with-fes-cycling-post-sci-100514216","NCT05975606","Non-invasive Brain Stimulation Paired With FES Cycling Post SCI","Exploring the Effect of Non-invasive Brain Stimulation Paired With Functional Electrical Stimulation to Improve Lower Extremity Function Following Incomplete Spinal Cord Injury","Inclusion Criteria:\n\n* adult\n* having motor incomplete SCI with level C or D on the American Spinal Injury Association Impairment Scale (AIS) with the lesion at any level of the cord resulting from either traumatic or non-traumatic etiology who are at least one-year post-injury.\n* having non-progressive SCI\n* being able to walk independently for 10 meters without help from another person\n\nExclusion Criteria:\n\n* other orthopedic or neurological implications that affect the lower extremity function\n* contraindications to FES (e.g., implanted electronic devices, unhealed bone fractures, sever contractures, extreme osteoporosis or osteoarthritis)\n* contraindications to rTMS (e.g., metal implants, history of seizure, cochlear implants)",{"count":631,"type":21},14,[24],"This project is randomized controlled trial which will explore the effect of pairing repetitive Transcranial Magnetic Stimulation (rTMS) with Functional Electrical Stimulation (FES) Cycling on lower extremity function in people with incomplete spinal cord injury and compare the effects to each one of these interventions alone.",[635],"Incomplete Spinal Cord Injury",[637,638,639,640,641,642,643],"incomplete spinal cord injury","repetitive transcranial magnetic stimulation","functional electrical stimulation cycling","lower extremity function","walking speed","muscle strength","feasibility",{"date":599,"type":36},{"date":646,"type":36},"2023-09-19",{"date":648,"type":21},"2025-12",{"name":42,"class":43},""]